Hematological Anomalies in Children With Rasopathy

ConditionRAS Mutation
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeUp to 15
SponsorAssistance Publique - Hôpitaux de Paris

About this trial

During childhood, patients with RASopathies (Noonan syndrome and related diseases) can harbor various hematological anomalies ranging from isolated monocytosis, myelemia, thrombocytopenia or splenomegaly to myeloproliferative disorders. These anomalies may spontaneously disappear or persist, sometimes leading to juvenile myelomonocytic leukemia. Guidelines for initial screening and subsequent hematological follow-up have recently been published in France: peripheral blood analysis should be performed in all newly diagnosed patients and followed by biannual peripheral blood analysis in infants until the age of 2 years.

In order to describe the characteristics of these abnormalities in terms of their incidence, age of occurrence, evolution and relation to genotype, we are conducting a longitudinal prospective study whose aim is to analyze peripheral blood cell counts and smears at diagnosis and one year later. In patients \<3 years of age recruited at certain centers, biobanking of mononuclear cells will be performed. These data could yield a new insight into hematological anomalies in patients with RASopathies and thereby help physicians to determine the appropriate rhythm for hematological follow-up according to genotype.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age < 16 years

Patient newly diagnosed with genetically confirmed rasopathy : Noonan syndrome, type 1 neurofibromatosis, Noonan syndrome with multiple lentigines, CBL syndrome, Costello syndrome, cardiofaciocutaneous syndrome or Legius syndrome i.e. with a germline mutation of one of these genes: PTPN11, SOS1, NRAS, RAF1, BRAF, SHOC2, MEK1, MEK2, CBL, NF1, SPRED1, KRAS, HRAS, NF1, SHOC2, LZTR1, SOS2, RIT1, RASA2, RRAS, PPP1CB, or a new gene of interest published during the recruitment period

No history of hematological malignancy

Written informed consent obtained from the parents

Disqualifiers

History of malignant hematological pathology

Trial population

Patients aged 15 years old and younger with RASopathies (Noonan syndrome and related diseases)

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Proportion of patients with hematological abnormalities

Time frame
at inclusion (within 6 months after diagnosis)

Secondary outcomes

1

Proportion of patients with hematological abnormalities according to genetic abnormality

Time frame
at inclusion (within 6 months after diagnosis)
2

Proportion of patients with hematological abnormalities according to age

Time frame
at inclusion (within 6 months after diagnosis)
3

Proportion of patients with hematological abnormalities

Time frame
at 1 year after inclusion
4

Proportion of patients with hematological abnormalities according to age

Time frame
at 1 year after inclusion

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.